跳至主要内容
临床试验/JPRN-UMIN000010807
JPRN-UMIN000010807招募中未知

A study on the effect of improving the QOL (quality of life), response and safety of eribulin mesylate for inoperable or recurrent breast cancer - A Study on QOL, response and safety of eribulin for inoperable or recurrent breast cancer

Department of Breast Surgery, Nippon Medical School0 个研究点目标入组 100 人开始时间: 2013年5月26日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • - patients with advanced bone marrow suppression. - patients who has an anamnesis of hypersensitivity to the ingredient of this agent. - pregnant women or the women that may have become pregnant - patients simultaneously treatmented by trastuzumab or lapatinib. - patients who judged that it was unsuitable as other candidates

研究者

发起方
Department of Breast Surgery, Nippon Medical School

相似试验